AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
SAN ANTONIO -- Switching postmenopausal women with hormone-responsive breast cancer from adjunctive tamoxifen to anastrozole after 2-3 years has now for the first time been shown to result in significantly improved overall survival compared with 5 years on tamoxifen, Dr. Walter Jonat said at a breast cancer symposium sponsored by the Cancer Therapy and Research Center.
Prior randomized trials comparing the long-standard 5 years of adjunctive tamoxifen with the alternative of 2-3 years followed by a switch to an aromatase inhibitor for the balance of the 5 years of therapy have shown that switching resulted in substantially better disease-free survival; that is, fewer recurrences. The same has been seen in trials pitting 5 years of tamoxifen against 5 years of an aromatase inhibitor.
Dr. Jonat presented the results of a new metaanalysis of the three anastrozole (Arimidex) switching trials in which, as a result of expanded patient numbers, the switching strategy yielded a highly significant 29% reduction in total mortality.
"Survival is the important end point. It is what the patient wants to get from us .... These data confirm that postmenopausal women currently receiving adjuvant tamoxifen should be switched to anastrozole," ...
Source: HighBeam Research, Switch to anastrozole raises overall breast Ca survival.(News)